teneligliptin + empagliflozin

Teneligliptin + empagliflozin is a fixed-dose combination of two oral antidiabetic agents used for the management of type 2 diabetes mellitus. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, leading to increased insulin secretion and decreased glucagon secretion in a glucose-dependent manner. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by inhibiting renal glucose reabsorption, resulting in increased urinary glucose excretion. The combination targets complementary mechanisms to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy or dual therapy with other agents does not provide adequate glycemic control[3][6]. Empagliflozin also provides cardiovascular and renal benefits independent of its glycemic effects[3][4].

Other names

teneligliptin and empagliflozin fixed-dose combination